Small-molecule inhibitors targeting FOXM1: current challenges and future perspectives in cancer treatments
S Raghuwanshi, AL Gartel - Biochimica et Biophysica Acta (BBA)-Reviews …, 2023 - Elsevier
Forkhead box (FOX) protein M1 (FOXM1) is a critical proliferation-associated transcription
factor (TF) that is aberrantly overexpressed in the majority of human cancers and has also …
factor (TF) that is aberrantly overexpressed in the majority of human cancers and has also …
Regulation of HOX gene expression in AML
As key developmental regulators, HOX cluster genes have varied and context-specific roles
in normal and malignant hematopoiesis. A complex interaction of transcription factors …
in normal and malignant hematopoiesis. A complex interaction of transcription factors …
Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies
S Raghuwanshi, X Zhang, Z Arbieva, I Khan… - Cell Death …, 2024 - nature.com
Forkhead box protein M1 (FOXM1) is often overexpressed in human cancers and strongly
associated with therapy resistance and less good patient survival. The chemotherapy …
associated with therapy resistance and less good patient survival. The chemotherapy …
The Promise of Combination Therapies with FOXM1 Inhibitors for Cancer Treatment
N Merjaneh, M Hajjar, YW Lan, VV Kalinichenko… - Cancers, 2024 - mdpi.com
Simple Summary FOXM1 is an oncogenic transcription factor that has been implicated in
cancer progression, metastases, and chemotherapy resistance. Multiple small-molecule …
cancer progression, metastases, and chemotherapy resistance. Multiple small-molecule …
A novel peptide CP29L, selected from the phage displayed cyclic random heptapeptide library, demonstrates its potent inhibitory effects to liver cancer HCCLM3 cells …
X Hua, K Xiang, A Liang, M Chang, S Jia… - European Journal of …, 2025 - Elsevier
FOXM1 is the “Achilles' heel” of cancers and hence the potential therapeutic target for
anticancer drug discovery. In this work, we selected high affinity peptides against the protein …
anticancer drug discovery. In this work, we selected high affinity peptides against the protein …
Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies
A Gartel, S Raghuwanshi, X Zhang, Z Arbieva, Z Wang… - 2023 - ncbi.nlm.nih.gov
[WITHDRAWN] Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum
of cancer therapies - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …
of cancer therapies - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …